MP53-06 THE EFFECTIVE PERIOD OF FIRST ANDROGEN DEPRIVATION THERAPY BECOMES AN PROGNOSTIC THE EFFECTIVE PERIOD OF FIRST ANDROGEN-DEPRIVATION THERAPY BECOMES AN PROGNOSTIC FACTOR IN DOCETAXEL CHEMOTHERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER PATIENTS

Androgen Deprivation ◽

Effective Period ◽

Castration Resistant ◽

Docetaxel Chemotherapy

Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network

European Journal of Cancer ◽

10.1016/j.ejca.2021.06.034 ◽

2021 ◽

Vol 155 ◽

pp. 127-135

Author(s):

Susanna Bianchi ◽

Alessandra Mosca ◽

Alberto Dalla Volta ◽

Veronica Prati ◽

Cinzia Ortega ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Androgen Deprivation ◽

Phase Iii ◽

Castration Resistant ◽

Phase Iii Study

Clinical Outcomes of Continuous Addition of Androgen Deprivation Therapy During Docetaxel Chemotherapy for Patients With Castration-Resistant Prostate Cancer

The Korean Journal of Urological Oncology ◽

10.22465/kjuo.2017.15.2.59 ◽

2017 ◽

Vol 15 (2) ◽

pp. 59-65 ◽

Author(s):

Dong Hoon Lee ◽

Jung Ho Kim ◽

Won Ik Seo ◽

Jong Kil Nam ◽

Tae Nam Kim ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Outcomes ◽

Androgen Deprivation ◽

Castration Resistant ◽

Docetaxel Chemotherapy

MP09-19 PSA KINETICS IN INITIAL ANDROGEN DEPRIVATION THERAPY IS A PROGNOSTIC FACTOR IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER

The Journal of Urology ◽

10.1097/ju.0000000000000829.019 ◽

2020 ◽

Vol 203 ◽

pp. e123

Author(s):

Itsuto Hamano* ◽

Shingo Hatakeyama ◽

Shintaro Narita ◽

Masahiro Takahashi ◽

Toshihiko Sakurai ◽

...

Keyword(s):

Prostate Cancer ◽

Prognostic Factor ◽

Androgen Deprivation ◽

Psa Kinetics ◽

619P Maintenance versus discontinuation of androgen deprivation therapy during docetaxel administration with a continuous or an intermittent schedule in metastatic, castration resistant, prostate cancer patients: A multicenter randomized phase III study of the Piemonte Oncology Network

Annals of Oncology ◽

10.1016/j.annonc.2020.08.878 ◽

2020 ◽

Vol 31 ◽

pp. S512

Author(s):

A. Berruti ◽

A. Mosca ◽

S. Bianchi ◽

V. Prati ◽

C. Ortega ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Androgen Deprivation ◽

Phase Iii ◽

Intermittent Schedule ◽

Castration Resistant ◽

Phase Iii Study

Correction to: Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration

International Journal of Clinical Oncology ◽

10.1007/s10147-019-01395-0 ◽

2019 ◽

Vol 24 (5) ◽

pp. 554-556

Author(s):

Keisuke Shigeta ◽

Takeo Kosaka ◽

Hiroshi Hongo ◽

Yoshinori Yanai ◽

Kazuhiro Matsumoto ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Clinical Benefit ◽

Poor Response ◽

Androgen Deprivation ◽

How should we treat castration-resistant prostate cancer patients who have received androgen deprivation therapy (ADT) plus docetaxel upfront for hormone-sensitive diseae? Mature analysis of the GETUG-AFU 15 phase III trial

Annals of Oncology ◽

10.1093/annonc/mdw372.45 ◽

2016 ◽

Vol 27 ◽

pp. vi259 ◽

Author(s):

P. Lavaud ◽

G. Gravis ◽

C. Legoupil ◽

S. Foulon ◽

F. Joly ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Androgen Deprivation ◽

Phase Iii ◽

Phase Iii Trial ◽

Castration Resistant ◽

Hormone Sensitive ◽

Mature Analysis

Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration

International Journal of Clinical Oncology ◽

10.1007/s10147-018-01388-5 ◽

2019 ◽

Vol 24 (5) ◽

pp. 546-553 ◽

Author(s):

Keisuke Shigeta ◽

Takeo Kosaka ◽

Hiroshi Hongo ◽

Yoshinori Yanai ◽

Kazuhiro Matsumoto ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Clinical Benefit ◽

Poor Response ◽

Androgen Deprivation ◽

Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy

Prostate International ◽

10.1016/j.prnil.2015.10.015 ◽

2015 ◽

Vol 3 (4) ◽

pp. 123-126 ◽

Author(s):

Minyong Kang ◽

Sangchul Lee ◽

Jong Jin Oh ◽

Sung Kyu Hong ◽

Sang Eun Lee ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Systemic Chemotherapy ◽

Androgen Deprivation ◽

Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy

PLoS ONE ◽

10.1371/journal.pone.0229754 ◽

2020 ◽

Vol 15 (3) ◽

pp. e0229754

Author(s):

Zongwei Wang ◽

Tuo Deng ◽

Xingbo Long ◽

Xueming Lin ◽

Shulin Wu ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Androgen Deprivation ◽

Advanced age and early androgen deprivation therapy increase survival at different stages of the treatment in castration resistant prostate cancer patients

European Urology Open Science ◽

10.1016/s2666-1683(21)03147-5 ◽

2021 ◽

Vol 33 ◽

pp. S296

Author(s):

A.V. Ojeda Claro ◽

C.M. Fernández-Ávila ◽

M.F. Lorenzo Gómez ◽

M.J. Ledo Cepero ◽

E. Ruíz Guerrero ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Androgen Deprivation ◽

Advanced Age ◽